Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.75 |
| ▸ | RAB9A | P51151 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.63 |
| ▸ | RXRA | P19793 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31025721 | 1.00 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL9236564 | 0.94 | SMPD1 (0.73) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL3123036 | 0.92 | MAOB (0.64) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL4939800 | 0.90 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL242563 | 0.90 | MRGPRX4 (0.77) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL27881765 | 0.90 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL11277266 | 0.88 | MRGPRX4 (0.75) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL19225761 | 0.88 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL6812967 | 0.87 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL341137 | 0.87 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119191945-A | Synthetic method of (+/-) -guaifenesin-beta-O-4' -dihydroconiferyl alcohol | 盈科瑞（天津）创新医药研究有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-111253385-B | Heterocyclic compound, preparation method and application | 遵义医科大学珠海校区 | 2023-11-24 | — | — | CN | disclosed |
| CN-115433124-A | Preparation method of 4-chloro-6-methoxy-7-benzyloxy quinoline | 常州佳德医药科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-11447754-B2 | In vitro methods of chemical conversion using non-stereospecific glutathione lyases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-09-20 | — | — | US | disclosed |
| EP-2956138-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | ANGEX PHARMACEUTICAL, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-24 | — | — | US | disclosed |
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-24 | — | — | US | disclosed |
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | OXFORD FINANCE LLC | 2021-12-23 | — | — | US | disclosed |
| US-6005103-A | TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS | WARNER-LAMBERT COMPANY (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0888310-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| US-5808062-A | AIDS THERAPY | WARNER-LAMBERT COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1997034876-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1997-09-25 | — | — | WO | disclosed |
| CN-1155279-A | Neuroprotective 3-(piperidinyl-1)-chroman-4,7,-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkane alcohol | PFIZER (US) | 1997-07-23 | — | — | CN | disclosed |
| EP-0729466-A1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0729465-A1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995014013-A1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995014014-A2 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE, DAVIS & COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| US-4098816-A | HYPOGLYCEMIC AGENTS AND ANTILIPEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | TGFB1, TGFBR1, TGFBR2 | NPC1 1441/4885RAB9A 2472/4885SMN1; SMN2 2893/4885 |
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | NPC1 10/4885RAB9A 546/4885SMN1; SMN2 2990/4885 |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | UCK2, ULK2, CDK9 | NPC1 1857/4885RAB9A 1236/4885SMN1; SMN2 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.